Management of Idiopathic Intracranial Hypertension

Treatment Recommendations

The American Academy of Neurology recommends against using prednisone for patients with idiopathic intracranial hypertension (IIH) as it is not part of standard treatment protocols and may potentially exacerbate the condition 1, 2, 3
Current consensus guidelines do not include prednisone or other corticosteroids as recommended treatments for IIH, suggesting they could worsen rather than improve IIH 1, 2, 3
Acetazolamide is the first-line pharmacological treatment for symptomatic IIH patients or those with visual field/acuity loss, with a starting dose typically 250-500 mg twice daily, and a maximum dose of 4g daily 1, 5
Topiramate may be considered as an alternative due to its dual benefits of carbonic anhydrase inhibition and appetite suppression, with a weekly dose escalation from 25mg to 50mg twice daily 2, 5

NSAIDs or paracetamol are recommended for acute headache management in IIH patients 1, 5
Indomethacin may be particularly beneficial due to its effect on reducing intracranial pressure 1, 5
Migraine prophylactic agents may be used for headaches with migrainous features 1, 5
Opioids should be avoided for headache management in IIH 1, 5

Pregnant patients require special consideration, as acetazolamide is not recommended during pregnancy due to potential teratogenic effects, and topiramate is contraindicated due to clear evidence of higher rates of fetal abnormalities 3
For patients with progressive visual loss despite maximal medical therapy, CSF shunting procedures may be necessary 1, 2

Follow-up intervals should be based on papilledema grade and visual field status, with more frequent monitoring needed for severe or worsening cases 3